Treatment and outcomes of post-transplant lymphoproliferative disease: A single institution study

American Journal of Hematology

Volumn 82, Issue 3, 2007, Pages 208-214

  Buadi, Francis K ^a,b   Heyman, Meyer R ^a   Gocke, Christopher D ^a   Rapoport, Aaron P ^a   Hakimian, Roger ^a   Bartlett, Stephen T ^a   Sarkodee Adoo, Clarence ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TENNESSEE CANCER INSTITUTE   (United States)

Author keywords

Lymphoproliferative disorder; Post transplant

Indexed keywords

ACICLOVIR; ANTHRACYCLINE DERIVATIVE; ANTIVIRUS AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; GANCICLOVIR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; METHOTREXATE; PREDNISONE; RITUXIMAB; TACROLIMUS; VINBLASTINE; VINCRISTINE;

ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL STUDY; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG MEGADOSE; FEMALE; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; LYMPHOID HYPERPLASIA; LYMPHOPROLIFERATIVE DISEASE; MALE; OVERALL SURVIVAL; PANCREAS TRANSPLANTATION; POSTOPERATIVE COMPLICATION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; DISEASE-FREE SURVIVAL; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; RADIOTHERAPY; REOPERATION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33847685301     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20795     Document Type: Article

References (27)

1. Leblond V, Sutton L, Dorent R, et al. Lymphoproliferative disorders after organ transplantation: A report of 24 cases observed in a single center. J Clin Oncol 1995;13:961-968.
2. Dharnidharka VR, Tejani AH, Ho PL. Harmon WE. Post-transplant lymphoproliferative disorder in the United States: Young Caucasian males are at highest risk. Am J Transplant 2002;2:993-998.
3. Keay S, Oldach D, Wiland A, et al. Posttransplantation lymphoproliferative disorder associated with OKT3 and decreased antiviral prophylaxis in pancreas transplant recipients. Clin Infect Dis 1998;26:596-600.
4. Meador TL, Krebs TL, Cheong JJ, Daly B, Keay S, Bartlett S. Imaging features of posttransplantation lymphoproliferative disorder in pancreas transplant recipients. AJR Am J Roentgenol 2000;174:121-124.
5. Heller T, Drachenberg CB, Orens JB, Fantry GT. Primary post-transplant lymphoproliferative disorder of the gallbladder in a lung transplant patient presenting with acute cholecystitis. Transplantation 2000;69:668-670.
6. Drachenberg CB, Abruzzo LV, Klassen DK, et al. Epstein-Barr virus-related posttransplantation lymphoproliferative disorder involving pancreas allografts: Histological differential diagnosis from acute allograft rejection. Hum Pathol 1998;29:569-577.
7. Koffman BH, Kennedy AS, Heyman M, Colonna J, Howell C. Use of radiation therapy in posttransplant lymphoproliferative disorder (PTLD) after liver transplantation. Int J Cancer 2000;90:104-109.
8. Jaffe E, Harris N, Stein H, Vardiman J, editors. World Health Organization Classification of Tumors. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, Lyon: IARC Press; 2001.
9. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993;342: 1514-1516.
10. Dharnidharka VR, Ho PL, Stablein DM, Harmon WE, Tejani AH. Mycophenolate, tacrolimus and post-transplant lymphoproliferative disorder: A report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant 2002;6:396-399.
11. Dharnidharka VR, Sullivan EK, Stablein DM, Tejani AH, Harmon WE. Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 2001;71:1065-1068.
12. Gaillard S, Lachat V, Moulin B. Posttransplant lymphoproliferative disorders in renal allograft recipients: Report of 53 cases of a French multicenter study. PTLD French Working Group. Transpl Int 2000;13(Suppl. 1):S388-S393.
13. Penn I. Cancers in renal transplant recipients. Adv Ren Replace Ther 2000;7:147-156.
14. Penn I. De novo malignances in pediatric organ transplant recipients. Pediatr Transplant 1998;2:56-63.
15. Birkeland SA. De novo cancers complicating renal transplantation: Experience in the Nordic countries. Ann Transplant 1997; 2:22-26.
16. Bartlett ST, Farney AC, Jarrell BE, et al. Kidney transplantation at the University of Maryland. Clin Transpl 1998:177-185.
17. Boyle GJ, Michaels MG, Webber SA, et al. Posttransplantation lymphoproliferative disorders in pediatric thoracic organ recipients. J Pediatr 1997;131:309-313.
18. Nelson BP, Nalesnik MA, Bahler DW, Locker J, Fung JJ, Swerdlow SH. Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: A distinct entity? Am J Surg Pathol 2000;24:375-385.
19. Tsai DE, Hardy CL, Tomaszewski JE, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: Analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001; 71:1076-1088.
20. Penn I. Posttransplant malignancies. Transplant Proc 1999;31:1260-1262.
21. Swinnen LJ. Durable remission after aggressive chemotherapy for post-cardiac transplant lymphoproliferation. Leuk Lymphoma 1997;28:89-101.
22. Nalesnik MA, Jaffe R, Starzl TE, et al. The pathology of post-transplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 1988;133:173-192.
23. Nalesnik MA, Randhawa P, Demetris AJ, Casavilla A, Fung JJ. Locker J. Lymphoma resembling Hodgkin disease after post-transplant lymphoproliferative disorder in a liver transplant recipient. Cancer 1993;72:2568-2573.
24. Nalesnik MA. Clinicopathologic characteristics of post-transplant lymphoproliferative disorders. Recent Results Cancer Res 2002; 159:9-18.
25. Frizzera G, Hanto DW, Gajl-Peczalska KJ, et al. Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients. Cancer Res 1981;41:4262-4279.
26. Knowles DM, Cesarman E. Chadburn A, et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995;85:552-565.
27. Swerdlow SH. Classification of the posttransplant lymphoproliferative disorders: From the past to the present. Semin Diagn Pathol 1997;14:2-7.